Skip to main content

What you should know about wearable glucose monitors in wake of recall

The number of reported problems tied to millions of continuous glucose monitoring sensors that were recalled last year has grown.

About 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors manufactured by Abbott were recalled in November, because they might give low sugar readings that are incorrect.

In addition to seven deaths associated with the problem, there have been 860 serious injuries reported as of Jan. 7. That’s up from 736 at the time of the recall.

Even when working as designed, devices like these have benefits and drawbacks, according to Dr. Vandhna Sharma, an endocrinologist at MedStar Montgomery Medical Center in Maryland.

Continuous glucose monitoring systems, or CGMs, are often worn on the arm or abdomen and send readings to an app on your smartphone.

Sharma called them “excellent tools for identifying glucose patterns over time.” They are, however, different from glucometers, also known as blood glucose monitors or BGMs. CGMs monitor glucose levels in the fluid that surrounds cells, while glucometers check the levels in your blood.

The reading you get from a CGM may have a lag time of as much as 15 minutes behind what you get from a glucometer.

“If the CGM gives you a reading that’s low, you have to measure with a finger-stick,” Sharma said. “With any medical device, you have to ensure accuracy, especially periods of hypoglycemia.”

Another thing to keep in mind is whether a reading you’re getting makes sense with what your body is telling you.

“Whenever I give a patient a continuous glucose monitor — a CGM — I always advise them to correlate … the CGM reading to how they feel,” she said.

Tools to fight hantavirus show promise despite limited funding. Now researchers hope to continue

SANTIAGO, Chile (AP) — When a rare but deadly rodent-borne virus struck passengers on a cruise ship and seemed to be spreading, there were no treatments for those who fell ill and no vaccines to protect others. That was the case even though it wasn't a novel germ that the world had never seen before, like the virus that caused the coronavirus pandemic. It was a hantavirus, one of a family of viruses that have been known for decades and are thought to exist around the world. Teams of researchers, including in Chile, Argentina and the United States, have long been trying to find and develop drugs and vaccines. But because the viruses are relatively rare and don't spread easily between people, there hasn't been enough sustained investment by governments, global health groups, or drug companies to pay for the extensive safety and efficacy testing needed to make them available. Still, there have been some promising developments. Researchers on Wednesday published a hint that a drug used for an autoimmune disease may help hantavirus patients fight off the most deadly symptoms.
Read Next Story